Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 06835919

Next Previous
Drug Profile

PF 06835919

Alternative Names: PF-06835919

Latest Information Update: 04 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics; Hepatoprotectants; Small molecules
  • Mechanism of Action Fructokinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 09 Sep 2024 Efficacy data from a phase II trial in Non-alcoholic fatty liver disease presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
  • 22 Jun 2022 Phase-II clinical trials in Non-alcoholic fatty liver disease in Netherlands (PO) (EudraCT2021-006677-26)
  • 28 Jul 2021 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Belgium (PO) (Pfizer pipeline, July 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top